Current state and prospects of gout treatment in Korea

키워드

참고문헌 (96)

1. Roddy E, "Epidemiology of gout", Arthritis Res Ther, 12, pp.223~ (2010)
2. Chen-Xu M, "Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends : the National Health and Nutrition Examination Survey, 2007-2016", Arthritis Rheumatol, 71, pp.991~999 (2019)
3. Mattiuzzi C, "Recent updates on worldwide gout epidemiology", Clin Rheumatol, 39, pp.1061~1063 (2020)
4. Jin Su Park, "Trends of Gout Prevalence in South Korea Based on Medical Utilization: A National Health Insurance Service Database (2002∼2015)", 대한류마티스학회지, 27(3), pp.174~181 (2020), 대한류마티스학회[DOI]
5. Kuo CF, "Rising burden of gout in the UK but continuing suboptimal management : a nationwide population study", Ann Rheum Dis, 74, pp.661~667 (2015)
6. Rashid N, "Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system", J Rheumatol, 42, pp.504~512 (2015)
7. FitzGerald JD, "2020 American College of Rheumatology guideline for the management of gout", Arthritis Care Res(Hoboken), 72, pp.744~760 (2020)
8. Hui M, "The British Society for Rheumatology guideline for the management of gout", Rheumatology(Oxford), 56, pp.e1~e20 (2017)
9. Richette P, "2016 Updated EULAR evidence-based recommendations for the management of gout", Ann Rheum Dis, 76, pp.29~42 (2017)
10. Lorenzo JP, "2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout", Int J Rheum Dis, 25, pp.7~20 (2022)
11. Major TJ, "Evaluation of the diet wide contribution to serum urate levels : metaanalysis of population based cohorts", BMJ, 363, pp.k3951~ (2018)
12. Neogi T, "Alcohol quantity and type on risk of recurrent gout attacks : an internet-based case-crossover study", Am J Med, 127, pp.311~318 (2014)
13. Zhang Y, "Purine-rich foods intake and recurrent gout attacks", Ann Rheum Dis, 71, pp.1448~1453 (2012)
14. Choi HK, "Fructose-rich beverages and risk of gout in women", JAMA, 304, pp.2270~2278 (2010)
15. Juraschek SP, "Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials", Arthritis Care Res(Hoboken), 63, pp.1295~1306 (2011)
16. Stamp LK, "Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout : a pilot randomized controlled trial", Arthritis Rheum, 65, pp.1636~1642 (2013)
17. Li R, "Dietary factors and risk of gout and hyperuricemia : a meta-analysis and systematic review", Asia Pac J Clin Nutr, 27, pp.1344~1356 (2018)
18. Yokose C, "The role of diet in hyperuricemia and gout", Curr Opin Rheumatol, 33, pp.135~144 (2021)
19. Nguyen UD, "Obesity paradox in recurrent attacks of gout in observational studies: clarification and remedy", Arthritis Care Res(Hoboken), 69, pp.561~566 (2017)
20. Dalbeth N, "Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes : a prospective longitudinal study", Ann Rheum Dis, 73, pp.797~802 (2014)
21. Dessein PH, "Beneficial effects of weight loss associated with moderate calorie", carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout : a pilot study, 2000, pp.59, 539~543
22. Scheepers LE, "Medication adherence among patients with gout : a systematic review and meta-analysis", Semin Arthritis Rheum, 47, pp.689~702 (2018)
23. Yin R, "Rate of adherence to uratelowering therapy among patients with gout : a systematic review and meta-analysis", BMJ Open, 8, pp.e017542~ (2018)
24. Briesacher BA, "Comparison of drug adherence rates among patients with seven different medical conditions", Pharmacotherapy, 28, pp.437~443 (2008)
25. Schlesinger N, "Local ice therapy during bouts of acute gouty arthritis", J Rheumatol, 29, pp.331~334 (2002)
26. Dincer HE, "Asymptomatic hyperuricemia : to treat or not to treat", Cleve Clin J Med, 69, pp.594~ (2002)[DOI]
27. Skoczynska M, "Pathophysiology of hyperuricemia and its clinical significance : a narrative review", Reumatologia, 58, pp.312~323 (2020)
28. Wang J, "Hyperuricemia and risk of incident hypertension : a systematic review and meta-analysis of observational studies", PLoS One, 9, pp.e114259~ (2014)
29. Li L, "Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? : a systematic review and meta-analysis based on observational cohort studies", BMC Nephrol, 15, pp.122~ (2014)
30. Kim SY, "Hyperuricemia and coronary heart disease: a systematic review and meta-analysis", Arthritis Care Res(Hoboken), 62, pp.170~180 (2010)
31. Kim SY, "Hyperuricemia and risk of stroke : a systematic review and meta-analysis", Arthritis Rheum, 61, pp.885~892 (2009)
32. Sandoval-Plata G, "Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank", Rheumatology(Oxford), 60, pp.3243~3251 (2021)
33. Kimura K, "Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia : a randomized trial", Am J Kidney Dis, 72, pp.798~810 (2018)
34. Campion EW, "Asymptomatic hyperuricemia : risks and consequences in the Normative Aging Study", Am J Med, 82, pp.421~426 (1987)
35. Martinon F, "Gout-associated uric acid crystals activate the NALP3inflammasome", Nature, 440, pp.237~241 (2006)
36. Martinon F, "The inflammasome : a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta", Mol Cell, 10, pp.417~426 (2002)
37. Roddy E, "Open-label randomised pragmatic trial(CONTACT)comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care", Ann Rheum Dis, 79, pp.276~284 (2020)
38. Rainer TH, "Oral prednisolone in the treatment of acute gout : a pragmatic, multicenter, double-blind, randomized trial", Ann Intern Med, 164, pp.464~471 (2016)
39. Janssens HJ, "Use of oral prednisolone or naproxen for the treatment of gout arthritis : a double-blind, randomised equivalence trial", Lancet, 371, pp.1854~1860 (2008)
40. Man CY, "Comparison of oral prednisolone", paracetamol and oral indomethacin, Ann Emerg Med, pp.2007, 49[DOI]
41. Terkeltaub RA, "High versus low dosing of oral colchicine for early acute gout flare : twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study", Arthritis Rheum, 62, pp.1060~1068 (2010)
42. Terkeltaub RA, "Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4", P-glycoprotein inhibitors, 2011, pp.63, 2226~2237
43. Wechalekar MD, "Intraarticular glucocorticoids for acute gout", Cochrane Database Syst Rev, 4, pp.CD009920~ (2013)
44. Schlesinger N, "A survey of current evaluation and treatment of gout", J Rheumatol, 33, pp.2050~2052 (2006)
45. Schlesinger N, "Canakinumab for acute gouty arthritis in patients with limited treatment options : results from two randomised, multicentre, activecontrolled, double-blind trials and their initial extensions", Ann Rheum Dis, 71, pp.1839~1848 (2012)
46. Janssen CA, "Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, activecomparator, non-inferiority trial", Rheumatology(Oxford), 58, pp.1344~1352 (2019)
47. Terkeltaub RA, "Rilonacept in the treatment of acute gouty arthritis : a randomized, controlled clinical trial using indomethacin as the active comparator", Arthritis Res Ther, 15, pp.R25~ (2013)
48. Marchetti C, "OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation", Proc Natl Acad Sci U S A, 115, pp.E1530~E1539 (2018)
49. Spencer K, "Patient and provider barriers to effective management of gout in general practice : a qualitative study", Ann Rheum Dis, 71, pp.1490~1495 (2012)
50. Wortmann RL, "Effect of prophylaxis on gout flares after the initiation of uratelowering therapy : analysis of data from three phase III trials", Clin Ther, 32, pp.2386~2397 (2010)
51. Yamanaka H, "Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of uratelowering therapy : results from FORTUNE-1, a prospective, multicentre randomised study", Ann Rheum Dis, 77, pp.270~276 (2018)
52. Borstad GC, "Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis", J Rheumatol, 31, pp.2429~2432 (2004)
53. Choi HJ, "Current gout treatment and flare in South Korea : prophylactic duration associated with fewer gout flares", Int J Rheum Dis, 20, pp.497~503 (2017)
54. Ahn SM, "Comparative efficacy of low-dose versus regular-dose colchicine to prevent flares in gout patients initiated on urate-lowering therapies", Rheumatology(Oxford), 61, pp.223~229 (2021)
55. Pisaniello HL, "Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease : a Gout, Hyperuricemia and Crystal-Associated Disease Network(G-CAN)-initiated literature review", Arthritis Res Ther, 23, pp.130~ (2021)
56. Hill EM, "Does starting allopurinol prolong acute treated gout? : a randomized clinical trial", J Clin Rheumatol, 21, pp.120~125 (2015)
57. Taylor TH, "Initiation of allopurinol at first medical contact for acute attacks of gout : a randomized clinical trial", Am J Med, 125, pp.1126~1134 (2012)
58. Doherty M, "Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout : a randomised controlled trial", Lancet, 392, pp.1403~1412 (2018)
59. Dalbeth N, "Effects of allopurinol dose escalation on bone erosion and urate volume in gout : a dual-energy computed tomography imaging study within a randomized, controlled trial", Arthritis Rheumatol, 71, pp.1739~1746 (2019)
60. Stamp LK, "Allopurinol hypersensitivity : investigating the cause and minimizing the risk", Nat Rev Rheumatol, 12, pp.235~242 (2016)
61. Park HJ, "Unique clinical characteristics and prognosis of allopurinol-induced severe cutaneous adverse reactions", J Allergy Clin Immunol Pract, 7, pp.2739~2749 (2019)
62. Stamp LK, "How to prevent allopurinol hypersensitivity reactions?", Rheumatology (Oxford), 57(suppl_1), pp.i35~i41 (2018)
63. Lee KW, "Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and-DQB1 genes in the Korean population", Tissue Antigens, 65, pp.437~447 (2005)
64. González-Galarza FF, "Allele frequency net 2015 update : new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations", Nucleic Acids Res, 43(Database issue), pp.D784~D788 (2015)
65. Park DJ, "Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea", Arthritis Care Res(Hoboken), 67, pp.280~287 (2015)
66. Stamp LK, "A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout", Ann Rheum Dis, 76, pp.1522~1528 (2017)
67. "Zyloprim" (2018)[URL]
68. Altan A, "A real-world study of switching from allopurinol to febuxostat in a health plan database", J Clin Rheumatol, 21, pp.411~418 (2015)
69. Kang EH, "Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout", Eur Heart J, 42, pp.4578~4588 (2021)
70. Edwards NL, "Febuxostat: a new treatment for hyperuricaemia in gout", Rheumatology (Oxford), 48(Suppl 2), pp.ii15~ii19 (2009)
71. White WB, "Cardiovascular safety of febuxostat or allopurinol in patients with gout", N Engl J Med, 378, pp.1200~1210 (2018)
72. Chung Min Kyung, "Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence", Journal of Korean Medical Science, 36(32), pp.1~9 (2021), 대한의학회[DOI]
73. Kim A, "Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout : an 8-year retrospective cohort study", Clin Rheumatol, 39, pp.3769~3776 (2020)
74. Sang-Hyon Kim, "Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis", The Korean Journal of Internal Medicine, 35(4), pp.998~1003 (2020), 대한내과학회[DOI]
75. Choi SY, "Efficacy and tolerability of febuxostat in gout patients on dialysis", Intern Med J, 51, pp.348~354 (2021)
76. "Uloric" (2017)[URL]
77. Becker MA, "Febuxostat compared with allopurinol in patients with hyperuricemia and gout", N Engl J Med, 353, pp.2450~2461 (2005)
78. Schumacher HR Jr, "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout : a 28-week, phase III, randomized, double-blind, parallel-group trial", Arthritis Rheum, 59, pp.1540~1548 (2008)
79. 박성환, "The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout", 대한류마티스학회지, 20(4), pp.223~230 (2013), 대한류마티스학회
80. Zhang M, "Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol : population-based cohort study", Circulation, 138, pp.1116~1126 (2018)
81. Mackenzie IS, "Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout(FAST) : a multicentre, prospective, randomised, open-label, non-inferiority trial", Lancet, 396, pp.1745~1757 (2020)
82. Reinders MK, "Efficacy and tolerability of urate-lowering drugs in gout : a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol", Ann Rheum Dis, 68, pp.51~56 (2009)
83. Reinders MK, "A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg", day versus benzbromarone 100-200 mg, Ann Rheum Dis, pp.2009, 68[DOI]
84. Azevedo VF, "Benzbromarone in the treatment of gout", Adv Rheumatol, 59, pp.37~ (2019)
85. Lee MH, "A benefit-risk assessment of benzbromarone in the treatment of gout : was its withdrawal from the market in the best interest of patients?", Drug Saf, 31, pp.643~665 (2008)
86. "Duzallo and Zurampic: product discontinuation" (2022)[URL]
87. "Medicines “Duzallo”" (2022)[URL]
88. Kuriyama S, "Dotinurad : a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia", Clin Exp Nephrol, 24(Suppl 1), pp.1~5 (2020)
89. Sundy JS, "Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout", Arthritis Rheum, 56, pp.1021~1028 (2007)
90. Sundy JS, "Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment : two randomized controlled trials", JAMA, 306, pp.711~720 (2011)
91. Lipsky PE, "Pegloticase immunogenicity : the relationship between efficacy and antibody development in patients treated for refractory chronic gout", Arthritis Res Ther, 16, pp.R60~ (2014)
92. Keenan RT, "The effect of immunomodulators on the efficacy and tolerability of pegloticase : a systematic review", Semin Arthritis Rheum, 51, pp.347~352 (2021)
93. Waldman B, "Effect of fenofibrate on uric acid and gout in type 2 diabetes : a posthoc analysis of the randomised, controlled FIELD study", Lancet Diabetes Endocrinol, 6, pp.310~318 (2018)
94. Choi HK, "Antihypertensive drugs and risk of incident gout among patients with hypertension : population based case-control study", BMJ, 344, pp.d8190~ (2012)
95. Davies MJ, "Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus", Diabetes Obes Metab, 17, pp.426~429 (2015)
96. Raja R, "Hyperuricemia associated with thiazide diuretics in hypertensive adults", Cureus, 11, pp.e5457~ (2019)

관련 논문AI추천